Novo Holdings saw its assets shrink by a third last year as part of the fallout of Novo Nordisk’s nosediving share price. | ...

Vistagen Therapeutics is doubling down on its lead social anxiety candidate, even after the asset failed a phase 3 trial last December. | Vistagen Therapeutics is doubling down on its lead social ...

Regenxbio has guided its Duchenne muscular dystrophy (DMD) gene therapy candidate through another test, reporting a clean ...

Three of the top diabetes tech companies put forward new clinical data this week, making the case for their continuous glucose monitors and insulin pumps as they look to expand their reac | Three ...

An Ultragenyx gene therapy has scored a win at the midway point of its phase 3 trial, successfully reducing ammonia levels in patients with a rare urea cycle disorder.

French biotech Enodia Therapeutics is paying $1 million upfront in a backloaded deal for Kezar Life Sciences’ preclinical protein degradation program. | French biotech Enodia Therapeutics is paying $1 ...

BridgeBio Pharma has taken another step toward the potential approval of its muscle weakness drug candidate BBP-418, reporting statistically significant phase 3 efficacy data that analysts have deemed ...

“Strategic transformations are a common and often successful approach in biotechnology,” Rami Levin, who took over as CEO of ...

Evotec has escalated its already substantial reorganization, plotting an additional round of layoffs and site closures that will ...

According to a report from Bloomberg, the pro-Iran group Handala has publicly taken credit for the incident on social media, in response to the U.S. and Israeli strikes on the country, with claims of ...

BD has inked a technological partnership with automation provider Sinteco, aimed at pharmacy robotics. | The goal is to ...

A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way ...